Implications of the Latest Expanded Label of 177 Lu-PSMA-617 for Nuclear Medicine Practice
On July 31, 2026, the Food and Drug Administration expanded the label of 177Lu-PSMA-617 ([1][1]) to include the treatment of men who have metastatic androgen pathway modulator–sensitive/–naïve (mAPMS/N) prostate cancer (PC) (previously referred to as metastatic hormone-sensitive prostate cancer
Authors
- Steven P. Rowe (ORCID: https://orcid.org/0000-0003-2897-4694)
- Michael A. Gorin (ORCID: https://orcid.org/0000-0002-8315-6603)
- Oliver Sartor
- Scott Tagawa
- Kevin Courtney
- Ken Herrmann
- Frankis G. Almaguel
- Michael J. Morris
Institutions
- Tulane University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Loma Linda University (US)
- Weill Cornell Medicine (US)
- University of Duisburg-Essen (DE)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2026-09-24
- DOI
- https://doi.org/10.2967/jnumed.126.273661
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00